Proteasome Inhibitors Market Growth Outlook Through 2024-2033

Overview and Scope
Proteasome inhibitors refer to a class of drugs that interfere with the activity of proteasomes, which are cellular complexes responsible for degrading proteins in a controlled manner. Proteasome inhibitors are primarily used to treat certain types of cancer, particularly multiple myeloma, and some forms of lymphoma, demonstrating significant efficacy in targeting cancer cells and inducing cell death.

Sizing and Forecast
The proteasome inhibitors market size has grown strongly in recent years. It will grow from $1.86 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to scientific breakthroughs, clinical research and trials, fda approvals, rising cancer cases, advancements in drug delivery.

The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to precision medicine approaches, next-generation inhibitors, healthcare infrastructure growth, targeted therapies combination, emerging markets adoption. Major trends in the forecast period include immunotherapy combinations, selective proteasome inhibition, longer half-life inhibitors, oral formulations, resistant cancer variant treatments.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

Segmentation & Regional Insights
The proteasome inhibitors market covered in this report is segmented –

1) By Product: Velcade, Kyprolis, Ninlaro, Other Products
2) By Drugs: Bortezomib, Carfilzomib, Ixazomib
3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospital, Specialty Clinics, Other End-Users

North America was the largest region in the proteasome inhibitors market in 2023. The regions covered in the proteasome inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12251&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of pancreatic cancer is expected to propel the growth of the proteasome inhibitors market going forward. Pancreatic cancer is a type of cancer that develops in the cells of the pancreas, an organ located in the abdomen behind the stomach. Proteasome inhibitors are primarily used to treat pancreatic cancer, where proteasome plays a critical role in promoting cell survival and growth by degrading proteins that regulate cell cycle progression and cell death. It disrupts cancer cell survival and inhibits tumor growth and metastasis. For instance, in March 2023, according to the reports by the American Society of Clinical Oncology (ASCO), a US-based professional organization for oncology professionals, an estimated 64,050 adults in the US were diagnosed with pancreatic cancer by 2023, and 50,550 people died of pancreatic cancer. Furthermore, globally, 495,773 people were diagnosed, and 466,003 died of pancreatic cancer in 2020. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the proteasome inhibitors market.

Key Industry Players

Major companies operating in the proteasome inhibitors market report are Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeutics Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.

The proteasome inhibitors market report table of contents includes:

1. Executive Summary
2. Proteasome Inhibitors Market Characteristics
3. Proteasome Inhibitors Market Trends And Strategies
4. Proteasome Inhibitors Market – Macro Economic Scenario
5. Global Proteasome Inhibitors Market Size and Growth
.
.
.
31. Proteasome Inhibitors Market Other Major And Innovative Companies
32. Global Proteasome Inhibitors Market Competitive Benchmarking
33. Global Proteasome Inhibitors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Proteasome Inhibitors Market
35. Proteasome Inhibitors Market Future Outlook and Potential Analysis
36.Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model